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A B S T R A C T
Aim. The aim of this study was to examine the relationship between sexual dysfunction, repeat biopsies and other
demographic and clinical factors in men on active surveillance (AS).
Methods. Patient-reported outcomes (PROs) measures were administered at enrollment and every 6 months to
assess quality of life (QOL), psychosocial and urological health outcomes. Using mixed-effects models, we examined
the impact of repeat biopsies, total number of cores taken, anxiety, age, and comorbidity on sexual function over the
ﬁrst 24 months of enrolling in AS.
Main Outcome Measures. PROs included the Expanded Prostate Cancer Index Composite-26 (EPIC-26) Sexual
Function (SF) subscale, the American Urological Association-Symptom Index (AUA-SI), and the Memorial Anxiety
Scale for Prostate Cancer (MAX-PC).
Results. At enrollment (n = 195), mean age was 66.5 ± 6.8 with a mean EPIC-26 SF score of 61.4 ± 30.4. EPIC-26
SF scores steadily decreased to 53.9 ± 30.7 at 24 months (P < 0.01). MAX-PC scores also progressively decreased
over time (P = 0.03). Factors associated with lower EPIC-26 scores over time included age, unemployed status,
diabetes, coronary artery disease, and hypertension (all P < 0.05). Higher prostate-speciﬁc antigen (PSA) was
associated with a more rapid decline in EPIC-26 SF over time (P = 0.03). In multivariable analysis, age, diabetes, and
PSA × time interaction remained signiﬁcant predictors of diminished sexual function. Anxiety, number of biopsies,
and total cores taken did not predict sexual dysfunction or change over time in our cohort.
Conclusions. Men on AS experienced a gradual decline in sexual function during the ﬁrst 24 months of enrollment.
Older age, PSA × time, and diabetes were all independent predictors of diminished sexual function over time.
Anxiety, AUA-SI, the number of cores and the number of biopsies were not predictors of reduced sexual function in
men in AS. Pearce SM, Wang CHE, Victorson DE, Helfand BT, Novakovic KR, Brendler CB, and Albaugh
JA. A longitudinal study of predictors of sexual dysfunction in men on active surveillance for prostate cancer.
Sex Med 2015;3:156–164.
Key Words. Prostate Cancer; Erectile Dysfunction; Sexual Dysfunction; Active Surveillance; Quality of Life
Research support: No outside funding was used in this project.
Sex Med 2015;3:156–164 © 2015 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.
Introduction
Active surveillance (AS) has become a viablealternative to surgery and radiation in the
management of men with low risk for prostate
cancer (PCa). While it is currently underutilized,
with only 9% of eligible men choosing AS [1], one
would expect that AS will become a more popular
treatment option as more long-term outcomes
data become available. One clear advantage of AS
is to minimize morbidity such as sexual dysfunc-
tion (SD) associated with radical prostatectomy
(RP) and radiation therapy (RT). Nonetheless, it
has been demonstrated that men on AS also expe-
rience some degree of SD [2–5].
As measured by the Sexual Health Inventory for
Men (SHIM), 49% of men on AS for low-risk PCa
experience erectile dysfunction (ED), the most
common form of SD [2]. While not directly com-
parable with the AS population, the multicenter
Prostate Cancer Intervention Versus Observation
Trial (PIVOT) study reported SD in 44% of men
being observed for PCa compared with 81% of
patients undergoing RP at a median of 2 years
after diagnosis [3]. It is not surprising that older
men with PCa report SD, but 80% of men under-
going watchful waiting describe SD as a major
issue compared with 46% of age-matched controls
over an average follow-up of 12.2 years in a
population-based Scandinavian study [4]. A recent
study comparing men on AS with patients under-
going radical therapy (RT or RP) found that men
on AS were more often sexually active compared
with men who underwent local therapy. Among
men who were sexually active, 44–51% of men on
AS reported difﬁculty achieving or maintaining an
erection compared with 84–85% of men in the
treatment group [5]. Sexually inactive men on AS
were also less likely to attribute their inactivity to
ED [5]. Taken together, the data shown earlier
indicate that while AS has a much more favorable
risk proﬁle compared with radical therapy, SD
remains a signiﬁcant problem for men being fol-
lowed for low risk disease.
A thorough review of the existing literature has
revealed a number of potential predictive factors
for SD among men on AS including body mass
index (BMI), prostate volume, number of cores
taken at prostate biopsy (PB), frequency of PB, and
psychosocial factors such as the anxiety [6].
However, examination of the association between
PB and SD has yielded conﬂicting results with
some data indicating no adverse effect of PB on
erectile function [7–9], and other studies suggest-
ing both short- and long-term SD as a result of PB
[10–12]. A retrospective study of men on AS found
that increased biopsy number correlated with
decreased SHIM scores, but age, prostate volume,
and prostate-speciﬁc antigen (PSA) had no rela-
tion to decline in SHIM scores [12]. The
psychologic interplay of AS and sexual function is
highlighted by the ﬁnding that 6% of men expe-
rience some degree of SD in anticipation of a PB
[13]. There is evidence that that men diagnosed
with PCa after PB experience a greater decline in
erectile function compared with men with benign
biopsy results, indicating a potential psychologic
effect of the cancer diagnosis on erectile function
[14]. Additionally, there is evidence that increased
levels of depression and anxiety are associated with
decreased sexual function in men during the ﬁrst 3
years after RP after controlling for age, cancer
characteristics, and receipt of salvage treatment
[15]. As most previous studies examining sexual
function in men on AS have been cross-sectional,
there is limited understanding of predictors of SD
over time in this patient population. In order to
effectively counsel patients regarding the risks of
AS, we need a better understanding of factors that
are predictive of SD among men on AS.
Aims
SD over time in men on AS for PCa may be related
to speciﬁc patient demographics, clinical character-
istics and psychosocial parameters. We sought to
examine the relationship between SD and demo-
graphic, clinical, and patient-reported outcome
(PRO) data to determine predictive factors of SD in
a longitudinal observation trial of men on AS.
Methods
Study Population
As part of a prospective, longitudinal, observa-
tional Institutional Review Board-approved AS
protocol, several PROs measures were adminis-
tered at enrollment and during follow-up. After
enrollment a conﬁrmatory biopsy was done on
each participant, followed by a PSA and exam at
regular 6-month intervals. Subsequent biopsies
occur every 2 years unless otherwise indicated by
changes in PSA or exam. PROs were used to assess
how AS inﬂuences quality of life (QOL), psycho-
social and urological health outcomes. Informed
written consent was obtained from all participants.
All men were diagnosed with PCa prior to enroll-
ment. Men considered for AS under our study
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protocol met the following criteria based upon
12-core diagnostic transrectal ultrasound
(TRUS)-biopsy and digital rectal exam: clinical
stage ≤T2a, Gleason score ≤6, ≤3 cores positive,
maximum involvement of any core <50%, and
tumor volume ≤5% of total biopsy volume. Prior
to enrollment, all men received consultation
regarding the treatment options for early stage
PCa and declined all of the other treatment
options including surgery, external beam RT,
brachytherapy, and hormonal therapy. In order to
be eligible for enrollment, men must not had
received any prior treatment for their PCa, other
than medications that inhibit 5 alpha-reductase
including ﬁnasteride and dutasteride.
Main Outcome Measures
Demographic and Clinical Information
Demographic and clinical information such as age,
BMI, comorbidity, PSA, and prostate volume was
attempted to be collected for all participants.
Comorbid conditions such as diabetes, neurologic
disorders (such as lumbar disc disease and stroke),
coronary artery disease (CAD), hypertension,
hyperlipidemia, and sleep apnea were obtained by
diagnosis codes from the electronic medical
record.
Expanded Prostate Cancer Index
Composite-26 (EPIC-26)
EPIC-26 [16] is an abbreviated version of the origi-
nal 50-item EPIC [17] and has previously under-
gone psychometric testing revealing adequate
properties for clinical research purposes in measur-
ing PCa-related QOL. The EPIC-26 contains
subscales of sexual functioning, urinary inconti-
nence, urinary irritation/obstruction, bowel func-
tion, and hormone therapy-related side effects.
The subscales have shown high correlations
(r’s ≥ 0.95), as well as internal consistency and test–
retest reliability (α ≥ 0.70; r ≥ 0.60). The EPIC-26
sexual function score ranges from 0 to 100, with
higher scores indicating better sexual function.
There are six items to address sexual function in the
EPIC-26 including ratings of ability to have erec-
tions, quality of erections, frequency of erections,
ability to orgasm, ability to function sexually and
how big of a problem is the sexual function (or lack
of function).
American Urological Association Symptom
Index (AUA-SI)
The AUA-SI [18] is a brief, validated self-report
measurement questionnaire that assesses the
impact of lower urinary tract symptoms (LUTS)
over the previous 4-week period. Previous psycho-
metric testing revealed good internal consistency
and test–retest reliability, and AUA scores distin-
guish individuals with benign prostate hyperplasia
from healthy controls [19].
Memorial Anxiety Scale for Prostate
Cancer (MAX-PC)
MAX-PC [20] is a self-reported 18-itemmeasure to
determine anxiety related to PCa. The MAX-PC
scores range from 0 to 54 with higher scores indi-
cating higher anxiety levels. The subscales include
PCa anxiety (scores range from 0 to 33), PSA
anxiety (0–9) and fear of recurrence (0–12). Previ-
ous psychometric testing revealed good internal
consistency reliability (α ≥ 0.90) and high correla-
tions with other common measures of anxiety, such
as the Hospital Anxiety and Depression Score-
Anxiety [21].
Statistic Analysis
Patient characteristics were summarized using
descriptive statistics (frequency counts and per-
centages for categorical variables; means and stan-
dard deviations for continuous variables). EPIC-
26, AUA-SI, and MAX-PC scores were compared
across time (at baseline, and 6, 12, 18, and 24
months) using mixed-effects models. The effect
size between baseline and subsequent follow-up
time points was computed using Cohen’s d [22].
Both univariate and multivariable mixed-effects
models (using baseline demographics and clinical
characteristics as ﬁxed effects and individual inter-
cepts as random effects) were constructed for the
EPIC-26 sexual scale to determine the predictors
of SD in men on AS. A time interaction effect was
also examined in each mixed-effects model to
compare the rate of change in sexual function over
time among various subgroups. For example,
PSA × time represents the impact of PSA on the
rate of change in EPIC-26 over time. Signiﬁcant
changes in EPIC-26 sexual scores over time were
determined using maximum likelihood estimating
methods with unstructured covariance controlling
for random effects of individual intercept. Only
predictors that were signiﬁcantly associated with
EPIC-26 sexual score in the univariate analysis
were included in the multivariable model. Statistic
testing was two-sided with a threshold of statistic
signiﬁcance at P < 0.05. All statistic analyses were
conducted in SAS 9.4 (SAS Institute, Cary, NC,
USA).
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Results
Baseline Patient Characteristics
Among the entire study cohort (n = 195), the mean
age was 66.5 ± 6.8 years and mean BMI was
28.2 ± 4.3 kg/m2 (Table 1). The majority were
white (84.6%), married (84.6%), employed
(45.1%), and had a college education or higher
(54.9%). PSA at enrollment was 5.2 ± 3.9 ng/mL
with a PSA density of 0.12 ± 0.09. The most
common comorbidity was hypertension (48.7%),
followed by hyperlipidemia (27.2%) and diabetes
(16.4%). At the time of enrollment into AS, the
majority of men had one to two prostate biopsies
(96.5%) and the mean number of cores taken was
12.4 ± 1.5.
Sexual Function, Anxiety and Urinary Symptoms
Over Time
The mean EPIC-26 sexual score was 61.4 ± 30.4 at
baseline and decreased to 53.9 ± 30.7 at 24 months
(Table 2). There was a gradual decline in EPIC-26
sexual score over time at −3.73 points per year
(P = 0.0014). While statistically signiﬁcant, the
effect size was small between baseline and 18
months (d = 0.23), and approached a medium
effect by 24 months (d = 0.35). Over time, there
was also a decline in total MAX-PC score
(P = 0.0287) and the PCa anxiety subscale score
(P < .0001). However, similar to declines in sexual
function, the magnitude of the decline in the
MAX-PC score and PCa anxiety subscore was
small between baseline and 24 months (d = 0.28
and d = 0.30, respectively). There were no signiﬁ-
cant trends in PSA anxiety (P = 0.8), fear of recur-
rence subscale scores (P = 0.6), and AUA-SI
urological symptom scores (P = 0.3) over time.
Table 1 Patient characteristics
Variables
All patients (N = 195)
n %
Age (year), mean ± SD 66.5 ± 6.8
45–59 29 14.9
60–70 114 58.4
70+ 52 26.7
BMI (kg/m2), mean ± SD 28.2 ± 4.3
<25 37 19.0
25–30 97 49.7
30+ 47 24.1
Missing 14 7.2
Race (n, %)
White 165 84.6
African American 13 6.7
Other 17 8.7
Marital status
Married 165 84.6
Not married 26 13.3
Missing 4 2.1
Employment
Work 88 45.1
Not work 80 41.0
Missing 27 13.8
Education
Less than college 49 25.1
College 40 20.5
Graduate degree 67 34.4
Missing 36 18.5
Prostate volume (g), mean ± SD 46.9 ± 24.7
PSA (ng/mL), mean ± SD 5.2 ± 3.9
PSA density, mean ± SD 0.12 ± 0.09
Comorbidity
Diabetes 32 16.4
Neurologic 13 6.7
Sleep disorder 22 11.3
CAD 26 13.3
Hyperlipidemia 53 27.2
Hypertension 95 48.7
Total number of cores taken, mean ± SD 12.4 ± 1.5
Number of biopsies
1 129 66.2
2 59 30.3
3 6 3.1
4 1 0.5
BMI = body mass index; CAD = coronary artery disease; PSA = prostate-
specific antigen; SD = standard deviation.
Table 2 Memorial anxiety, EPIC-26 sexual function, and AUA-SI symptom index scores over time
Variables
Time Time effect*
Baseline 6 months 12 months 18 months 24 months Coefficient P value
EPIC-26 sexual score (0–100)† 61.4 ± 30.4 59.8 ± 33.0 60.2 ± 30.9 57.7 ± 31.4 53.9 ± 30.7 −0.311 0.0014
MAX-PC total score (0–54)‡ 9.8 ± 8.0 8.0 ± 8.2 7.9 ± 7.6 8.0 ± 8.2 7.6 ± 7.1 −0.053 0.0287
Prostate cancer anxiety (0–33)§ 5.6 ± 6.0 4.7 ± 6.0 3.9 ± 5.3 3.9 ± 5.9 3.8 ± 4.9 −0.067 <0.0001
PSA anxiety (0–9)¶ 0.27 ± 0.72 0.33 ± 0.95 0.31 ± 0.87 0.34 ± 1.06 0.29 ± 0.85 0.001 0.8348
Fear of recurrence (0–12)** 3.8 ± 3.1 2.9 ± 2.9 3.7 ± 3.8 3.7 ± 3.7 3.6 ± 3.8 0.008 0.6169
AUA-SI symptom score (0–35)†† 6.9 ± 5.5 7.5 ± 5.6 7.3 ± 5.1 7.3 ± 5.5 7.7 ± 5.4 0.016 0.3183
*Mixed-effects models.
†Higher score indicates higher sexual function.
**
,†,‡,§,¶Higher score indicates greater anxiety.
††Higher score indicates worse AUA-SI urological symptom.
EPIC-26 = Expanded Prostate Cancer Index Composite-26; MAX-PC = Memorial Anxiety Scale for Prostate Cancer; PSA = prostate-specific antigen; AUA-
SI = American Urological Association-Symptom Index.
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Predictors of SD
Men had signiﬁcantly lower EPIC-26 sexual
scores over time if they were older (P < 0.01), not
employed (P < 0.01), had a history of diabetes
(P = 0.01), CAD (P < 0.01), or hypertension
(P = 0.03) (Table 3). Men with higher baseline PSA
had a more rapid decline in sexual function over
time (P = 0.03), while no other patient character-
istics had signiﬁcant time interaction effects.
Anxiety, number of biopsies, and total cores taken
did not predict SD over time in our cohort (all
P > 0.6). In the multivariable analysis, time on AS
(P < 0.01), older age (P < 0.01), diabetes (P = 0.04),
and PSA × time interaction (P = 0.04) remained
signiﬁcant predictors of reduced sexual function
(Table 4).
In order to compare changes in SD among men
undergoing AS to a similar cohort of men without
PCa, we obtained results from a previous study
reporting EPIC-26 sexual scores amongst a group
of community dwelling men [23]. Our cohort
exhibited a exhibited a similar EPIC-26 sexual
function score at baseline compared with men of
similar age without PCa [23], but after 24 months
of surveillance, the EPIC-26 sexual function
score was lower among men on AS (P < 0.05)
(Figure 1).
Discussion
Longitudinal data on the sexual function of men
on AS are scarce, and there is conﬂicting evidence
regarding the association between prostate biop-
sies and erectile function. Our study has several
interesting ﬁndings in this unique study popula-
tion. We found that sexual function and PCa
anxiety gradually decreased over the ﬁrst 24
months of enrollment among men on AS for PCa.
We identiﬁed length of time on surveillance, older
age at enrollment, and diabetes as independent risk
factors for reduced sexual function over time.
Table 3 Univariate analysis for EPIC-26 sexual function score over time
Variable
Fixed effect Time interaction effect*
Coefficient P value Coefficient P value
Age −2.0979 <.0001 −0.0160 0.1134
BMI −0.5005 0.3677 −0.0154 0.3410
Race (white) 7.3861 0.2906 −0.2670 0.2566
Marital status (married) 1.7483 0.7995 −0.1109 0.5831
Employment (employed) 18.0325 0.0002 0.1335 0.3498
Education (college or above) 5.0022 0.3595 −0.0188 0.9056
Prostate volume −0.1647 0.1080 −0.0041 0.2111
PSA −0.7686 0.2018 −0.0447 0.0292
PSA density −35.5273 0.2719 −0.5670 0.5374
Comorbidity
Diabetes −15.7067 0.0108 0.0913 0.6102
Neurologic −0.1463 0.1298 0.0326 0.9154
Sleep disorder −9.2508 0.1884 0.1658 0.4602
CAD −19.2249 0.0035 0.0343 0.8491
Hyperlipidemia 4.7292 0.3739 0.0642 0.6755
Hypertension −10.1293 0.0322 0.2048 0.1383
Total number of cores taken 0.0180 0.9910 0.0151 0.7701
Number of biopsies 0.9068 0.8203 0.0267 0.8031
MAX-PC total score −0.0238 0.8842 −0.0027 0.7766
Prostate cancer anxiety −0.1073 0.6354 −0.0040 0.7626
PSA anxiety 0.4702 0.7308 −0.1386 0.1249
Fear of recurrence 0.1264 0.7309 −0.0009 0.9681
AUA-SI symptom score −0.4468 0.0750 −0.0028 0.8276
*Time was significant in all univariate models.
BMI = body mass index; CAD = coronary artery disease; EPIC-26 = Expanded Prostate Cancer Index Composite-26;MAX-PC = Memorial Anxiety Scale for
Prostate Cancer; PSA = prostate-specific antigen; AUA-SI = American Urological Association-Symptom Index.
Table 4 Multivariable analysis for EPIC-26 sexual
functioning score
Variable* Coefficient P value
Age −1.99 <.0001
Employed 7.84 0.0752
Diabetes −11.84 0.0414
CAD −5.02 0.3994
Hypertension −3.56 0.4153
PSA 0.11 0.8457
Time −0.19 0.0045
PSA × time −0.044 0.0381
*Only variables that were found significant in the univariate analysis were
included in the multivariable mixed-effects model.CAD = coronary artery
disease; EPIC-26 = Expanded Prostate Cancer Index Composite-26;
PSA = prostate-specific antigen.
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Higher baseline PSA also resulted in a more rapid
decline in sexual function over time. Anxiety, BMI,
race, number of biopsies, and total cores taken did
not predict SD in our cohort.
Fujita et al. evaluated the erectile function of
152 men on an AS protocol by comparing base-
line 5-item SHIM scores to scores obtained at a
single cross-sectional time point [12]. With a
mean follow-up of 3.2 years and mean number of
biopsies of 2.3, they found that only the number
of biopsies was independently associated with
decreased SHIM scores. The change in SHIM
score in men who underwent 0 to 2 PBs was
−2.3 ± 0.7 compared with −5.7 ± 1.1 in men who
underwent 3 + PBs. Multivariable analysis also
indicated that age, prostate volume and PSA had
no association with SHIM changes; however, this
study did not analyze the impact of ED-related
comorbidities in their multivariable analysis. It
must be noted that men who underwent more
prostate biopsies were on AS longer; therefore,
the observed reductions in erectile function must
be interpreted with caution as it is well estab-
lished that erectile function declines over time in
men.
Braun et al. performed a retrospective review of
342 patients enrolled on an AS protocol between
2000 and 2011 [8]. At each clinic visit, patients were
asked to complete the Prostate Health-Related
Quality of Life (PHRQoL), which includes six
questions about erectile function similar to the
International Index of Erectile Function (IIEF).
Themedian age in this cohort was 64 years, median
number of biopsieswas 5, and themedian follow-up
was 3.5 years.During the ﬁrst 4 years of AS, erectile
function decreased by 1.0 point per year, and
similar declines were seen when stratiﬁed by
number of biopsies. Because their AS protocol
mandated annual PB, analysis of the effect of mul-
tiple biopsies was limited, but their results suggest
that number of biopsies does not have a large effect
on erectile function. Another recent study compris-
ing 427 men on AS used an adjusted SHIM score
accounting for sexual activity level to examine the
impact of PB on erectile function [9]. Median
follow-up was 3.2 years from PCa diagnosis, 69%
of patients had one prior biopsy, 16% had two
biopsies, and the remainder had three or more.
This study examined the association between PB
and erectile function between men and longitudi-
nally in the same patients. Neither erectile function
nor sexual activity status was associated with
number of PBs. Our study conﬁrms these ﬁndings
that the number of prostate biopsies and number of
cores taken are not associated with signiﬁcant
reductions in sexual function [8,9].
Figure 1 Sexual function score over time for men in active surveillance.
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PROs were collected every 6 months starting at
enrollment allowing for detailed longitudinal
evaluation of sexual function and identiﬁcation of
predictors of reduced sexual function over time.
This information may prove valuable for counsel-
ing patients who are considering AS. An overall
decline in sexual function was observed during the
24-month study period, with older age at enroll-
ment and longer time on surveillance as indepen-
dent predictors for reduced sexual function over
time. The observed small magnitude of decline is
conﬁrmed by recently published data from the
prospective Comparative Effectiveness Analysis of
Surgery and Radiation study of 3,691 men with
newly diagnosed PCa [24]. Pretreatment EPIC-26
SF scores decreased by 1.24 points with every 1
year increase in age. The Massachusetts Male
Aging Study also demonstrated an increased inci-
dence of ED with advancing age [25]. These ﬁnd-
ings further support our assertion that the decline
in sexual function observed in our AS cohort is
related to aging. In our AS cohort, total MAX-PC
scores and the PCa anxiety sub-scores also saw a
gradual, small decline over time. Our results
support data from a recent study of 150 Dutch
men with low-risk PCa managed with AS [26].
This study found that general anxiety and fear of
progression signiﬁcantly decreased during the ﬁrst
18 months of enrollment on AS. Reductions in
anxiety could be the result of increased patient
acceptance of AS as a safe management strategy for
PCa and better tolerance of the repeated PB and
PSA testing required for compliance with AS pro-
tocols. These ﬁndings are potentially important
for clinicians attempting to manage patient expec-
tations and may provide reassurance for patients
considering AS. While we did not identify a cor-
relation between MAX-PC scores and SD, studies
in men after surgical treatment for PC have
found that increased PCa anxiety is associated
with poor sexual satisfaction and function [27].
Taken together, men entering AS can anticipate an
age related decline in sexual function, but may
beneﬁt from reduced disease-related anxiety
over time.
General comorbidity scores have been associ-
ated with reduced overall sexual function in men
on AS; however, to our knowledge, individual
comorbidities as risk factors for decreased sexual
function have not been examined. We identify dia-
betes as an independent predictor of reduced sexual
function over time in men on AS. This adds to the
extensive body of literature supporting diabetes as a
risk factor for SD,with rates of EDamong diabetics
ranging from 32% to 90% depending on the
patient population, diabetes type, severity, and
duration of disease [28]. We also found that
increased baseline PSA predicted a more rapid
decline in sexual function over time. Considering
previous epidemiological studies, which have found
strong associations between benign prostatic
hyperplasia (BPH), LUTS and SD [29,30], it is
possible that the association between PSA and
declining SF in our study is related to the presence
of BPH in patients with higher PSA. However, we
did not identify LUTS or prostate volume as pre-
dictors of SD in our analysis, therefore, no deﬁni-
tive conclusions can be made.
The study had several limitations. We do not
have data on patient sexual function prior to diag-
nosis with PCa. The magnitude of change for
sexual function during the study period was rela-
tively small (−7.5 points from baseline to 24
months), which should be taken into consideration
when interpreting these data. The EPIC-26 looks
at erectile function (three out of the six items focus-
ing on erectile function) as part of overall sexual
function subscale and does not provide a validated,
focused assessment of erectile function domain spe-
ciﬁcally in comparison with IIEF. The IIEF-5 has
been added to the questionnaires given to partici-
pants more recently to capture more speciﬁc erec-
tile function information from participants. As ED
is the most common sexual complaint, it will be
helpful to have a validated assessment erectile func-
tion as a speciﬁc domain within overall sexual func-
tion. Comorbid conditions, which impact sexual
function, such as diabetes, hypertension and CAD,
were obtained from the medical record, which may
result in underreporting of comorbid disease preva-
lence. Unfortunately, we are unable to examine
more informative disease-speciﬁc measures such as
glycemic control and their role in SD among men
in our AS cohort. This would help differentiate the
impact of aging vs. the impact of comorbid disease
progression on erectile function. Longer follow-up
could also allow us to examine the effect of lifestyle
changes such as weight loss on sexual function over
time. Additionally, our study is limited by the lack
of an age-matched control group without PC,
which could better delineate the speciﬁc effect of
age and aging on sexual function. Because we
limited analysis to the ﬁrst 24months of enrollment
on AS, relatively few biopsies were performed and
follow-up was limited. Over 60% of patients in our
study had only one biopsy during the study period,
which limits our ability assess the impact of mul-
tiple prostate biopsies on sexual function. Future
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studies will need to evaluate sexual function over a
longer period of time because most men will be
maintained on an AS protocol for more than 2
years.
Conclusions
Men experienced decreased sexual function and a
decline in PCa anxiety over the ﬁrst 24 months of
enrollment on an AS protocol. Older age, time on
AS, and diabetes were all associated with declining
sexual function over time. Increased baseline PSA
was associated with a more rapid decline in sexual
function as well. Anxiety, AUA-SI, other comorbid
conditions, the number of cores, and the number
of biopsies were not associated with declining
sexual function in our study; however, longer-
follow-up with more patients is needed to draw
any deﬁnitive conclusions. Sexual function in men
undergoing AS is multifactorial and is inﬂuenced
by many factors including age, aging over time and
comorbid conditions rather than increased biopsy
exposure. Larger prospective multicenter clinical
trials using varied approaches to examine the
various factors that may impact sexual function are
needed to further determine the etiology of SD in
men in AS.
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